Publications by authors named "W Sibley"
Article Synopsis
- The first major trial for multiple sclerosis (MS) therapy, comparing corticotrophin to placebo, showed that large studies could be done for this variable disease.
- Adrenocorticotrophic hormone was eventually replaced by intravenous methylprednisolone (IVMP) for treating acute flare-ups due to its effectiveness in controlling inflammation.
- While long-term corticosteroid use has risks, pulsed IVMP appears to reduce brain atrophy, suggesting that more research on this technique could be beneficial.
We have analysed data on exacerbation rates, Expanded Disability Status Scale (EDSS) scores, and lesion burdens using the results of two neutralizing antibody (NAB) assays (CPE and MxA) from the pivotal relapsing-remitting multiple sclerosis (MS) trial of interferon beta-1b (IFNB) with a longitudinal approach, where the influence of NABs in individual patients is assessed by comparing responses during NAB-positive and NAB-negative periods. There are apparent influences on exacerbation rate related to dose of IFNB, titer level, and duration of positivity. With the MxA assay, exacerbation rates after switching to NAB-positive status are estimated to be 28% higher [95% confidence interval (CI): (-15%, 92%)] and -2% higher [95% CI: (-21%, 21%)] on the low- and high-dose IFNB arms, respectively.
View Article and Find Full Text PDFThe International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on the objective demonstration of dissemination of lesions in both time and space. Magnetic resonance imaging is integrated with dinical and other paraclinical diagnostic methods.
View Article and Find Full Text PDFCorticosteroids or ACTH for acute exacerbations in multiple sclerosis.
Cochrane Database Syst Rev
August 2001
Background: Corticosteroids are often used to improve the rate of recovery from acute exacerbation in multiple sclerosis (MS) patients. However, it is still unclear just how relatively effective these agents are and the type of drug, optimal dose, frequency, duration of treatment and route of administration are unknown.
Objectives: The object of this review was to determine the efficacy and safety of corticosteroids or ACTH in reducing the short and long term morbidity from MS.